TOKYO (Reuters) – Japan’s Fujifilm Holdings Corp said on Friday it had discontinued the development of its anti-influenza drug Avigan as a COVID-19 treatment.
The company had halted Avigan’s enrolment in a clinical trial in March.
(Reporting by Kantaro Komiya; Editing by Chang-Ran Kim)
